Table 1 Characteristics of the included studies
Study | Published year | Study type | No. of cases | Endpoints | Treatment regimen | Radiation dose (Gy) | Endostatin usage | Total duration of endostatin |
|---|---|---|---|---|---|---|---|---|
Jiang [16] | 2012 | Prospective cohort study | 25 | 1-, 2-yr OS rate, 1-, 2-yr LCR, OS, ORR, AEs | ERT | 60 | 15 mg/day IV for 7 days during the first week of RT | 7 days× 1 cycles |
Zhai [18] | 2019 | Single-arm prospective study | 67 | 1-, 2-, 3-yr PFS/OS rate, PFS,OS, ORR, AEs | ECRT | 60–66 | 7.5 mg/m2/day CIV for 5 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT | 5 days× 4 cycles |
Sun [21] | 2016 | Single-arm prospective study | 19 | ORR, PFS, OS, AEs | ECRT | 60–66 | 7.5 mg/m2/day IV for 14 days per 3 weeks during RT | 14 days× 2 cycles |
Bao [22] | 2015 | Single-arm prospective study | 48 | OS, 1-, 2-, 3-yr PFS/OS rate and LCR, PFS, ORR, AEs | ECRT | 60–66 | 7.5 mg/m2/day IV for 7 days before the beginning of RT, and then repeated at week 2, 4, and 6 during RT | 7 day× 4 cycles |
Tang [23] | 2016 | Single-arm retrospective study | 78 | PFS, OS, ORR | ECRT | 60–66 | 7.5 mg/m2/day IV over 4 h per day for 7 days, or CIV for 5 days, at week 1, 3, 5 and 7, endostatin administrated 1 week prior to CRT | 5/7 days× 4 cycles |
Wen [24] | 2009 | Prospective cohort study | 14 | ORR, PFS, 1-yr OS rate | ERT | 66–68 | 15 mg/day IV during the first three weeks of RT | 21 days× 1 cycles |
Chen [25] | 2017 | Prospective cohort study | 20 | ORR, PFS, OS, AEs | ERT | 60–66 | 15 mg/day IV for 14 days per three weeks during RT | 14 day×2 cycles |